Scientists are looking at whether children need to be double jabbed and, if so, which Covid vaccine would work best for the over-12s.
The Com-Cov 3 trial will seek to recruit 360 volunteers who will be enrolled in one of four arms of the study of Covid-19 vaccination schedules in in 12 to 16-year-olds.
It comes after first doses of the Pfizer vaccine for 12 to 15-year-olds in England were approved on Monday. Scotland, Northern Ireland and Wales also confirmed they will offer a jab to people in the same age range.Professor Matthew Snape, associate professor in paediatrics and vaccinology at the University of Oxford, and chief investigator on the trial, said: “This study will provide vital information on the range of options for immunising teenagers against Covid-19 in the UK.
“As well as looking at the standard two full doses of the Pfizer vaccine, we will look at how well volunteers respond when their second dose of Pfizer is half that of the first dose, or if different vaccines are used altogether, such as the vaccines manufactured by Moderna or Novavax.
“This will provide the JCVI (Joint Committee on Vaccination and Immunisation) with information crucial to informing their advice about immunising teenagers in the UK.”
What does the Covid vaccine trial involve?
Participants in the study will either receive two Covid-19 vaccines, with Pfizer as their first dose.
Those who have already received a dose of the Pfizer vaccine through the NHS can be enrolled at the time of their second dose.
What vaccine will be administered as the second jab?
Participants will be randomly allocated to receive either a full dose or half dose of the Pfizer-BioNTech vaccine, a full dose of the Novavax jab or a half dose of the Moderna vaccine as their second jab.
The study is backed through funding from the Vaccines Taskforce and National Institute for Health Research (NIHR) and run across four NIHR-supported sites by the National Immunisation Schedule Evaluation Consortium.
Listen to our coronavirus podcast:
Professor Andrew Ustianowski, NIHR clinical lead for the Covid-19 vaccination programme and joint national infection specialty lead, said: “It is important to establish the most effective vaccine doses for different population groups, and this latest study will help develop our understanding of immune responses for young people once vaccinated against Covid-19.”
Researchers hope to report initial results by December, and if the results are promising, regulators the Medicines and Healthcare products Regulatory Agency (MHRA) and JCVI would formally assess the safety and efficacy of any new vaccination process before advising whether it is rolled out to patients.
Anyone who is interested can register on comcovstudy.org.uk.